AbbVie

Graphic showing arrows missing the bullseye on a target
Biotech

Alector lays off 17% of staff after ph. 2 Alzheimer's drug fail

Alector's Alzheimer's asset has failed to slow disease progression in a phase 2 study, prompting the company to lay off 41 workers.
Gabrielle Masson Nov 26, 2024 4:50am
failure crash no fail rocket cancelled end

AbbVie's $9B schizophrenia prospect flunks phase 2 trials

Nov 11, 2024 10:06am
Halloween deal shake hands zombie

AbbVie pays $65M for options on EvolveImmune's T-cell engagers

Oct 31, 2024 10:00am
Alzheimers research brain scientist magnifying glass questions neuro

AbbVie inks $1.4B Aliada buyout to land ex-J&J Alzheimer's drug

Oct 28, 2024 10:00am
Brain and money connected by a thread on a white background

AbbVie makes Richter richer, paying $25M to form discovery pact

Oct 25, 2024 7:55am
Soccer ball flying into a net scoring a goal

AbbVie Parkinson's drug from $8.7B Cerevel buyout scores

Sep 26, 2024 10:45am